Order Article Reprints

Pleguezuelos P, Sibila M, Ramírez C, López-Jiménez R, Pérez D, Huerta E, Llorens AM, Pérez M, Correa-Fiz F, Mancera Gracia JC, et al. Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age. Vaccines. 2022; 10(12):2108. https://doi.org/10.3390/vaccines10122108

Pleguezuelos, Patricia, Marina Sibila, Carla Ramírez, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Anna Maria Llorens, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera Gracia, and et al. 2022. "Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age" Vaccines 10, no. 12: 2108. https://doi.org/10.3390/vaccines10122108

Pleguezuelos, P., Sibila, M., Ramírez, C., López-Jiménez, R., Pérez, D., Huerta, E., Llorens, A. M., Pérez, M., Correa-Fiz, F., Mancera Gracia, J. C., Taylor, L. P., Smith, J., Bandrick, M., Borowski, S., Saunders, G., Segalés, J., López-Soria, S., Fort, M., & Balasch, M. (2022). Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age. Vaccines, 10(12), 2108. https://doi.org/10.3390/vaccines10122108